The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects

• Published in: Veterinary & comparative oncology Vol. 15; no. 2; pp. 632 - 640
• Main Authors: Holtermann, N., Kiupel, M., Hirschberger, J.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.06.2017
• Subjects: Animals; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Cat Diseases - drug therapy; Cat Diseases - etiology; Cats; clinical pathology; comparative oncology; Female; Indoles - adverse effects; Indoles - therapeutic use; Injections - adverse effects; Injections - veterinary; Male; molecular diagnostics; oncology; Protein-Tyrosine Kinases - antagonists & inhibitors; Pyrroles - adverse effects; Pyrroles - therapeutic use; Sarcoma - drug therapy; Sarcoma - etiology; Sarcoma - veterinary; Soft Tissue Neoplasms - drug therapy; Soft Tissue Neoplasms - etiology; Soft Tissue Neoplasms - veterinary; surgical oncology; tyrosine kinase; molecular diagnostics; clinical pathology; oncology; tyrosine kinase; comparative oncology; surgical oncology
• ISSN: 1476-5810; 1476-5829
• DOI: 10.1111/vco.12207

Because of their locally invasive growth and high recurrence rate despite of aggressive local therapy, treatment of feline sarcomas is challenging. The tyrosine kinase inhibitor (TKI) toceranib is currently licensed for the treatment of canine mast cell tumours. There are only few reports about TKI usage in cats. Previous studies indicated promising potential of TKI for the treatment of feline injection site sarcoma (FISS). In this prospective clinical trial, 18 cats with unresectable FISS were treated at a target dosage of 3.25 mg kg−1 every other day to evaluate the clinical efficacy and toxicity of toceranib. There was no clinical response measurable. Adverse events were generally mild and temporary. Grade 3 or 4 adverse events developed infrequently and all resolved with drug holidays and dose reductions.